Abstract
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in 22 provinces of China. Fifty-four patients (7.3%) received monotherapy, 264 (36.0%) received chemoimmunotherapy, 395 (53.8%) received other combination regimens without rituximab, and 21 (2.9%) received ibrutinib. Using a multivariable Cox regression model, age > 65 years old, platelets <100 × 109/L, serum albumin <3.5 g/dl, β2 microglobulin concentration ≥4 mg/L and LDH ≥250 IU/L predicted poor OS. In summary, our study showed that frontline treatment choices for WM are widely heterogeneous. We validated most of the established prognostic factors in the rIPSS (age >65 years, LDH ≥250 IU/L, ALB <3.5 g/dl and β2 microglobulin ≥4 mg/L) together with PLT ≤ 100 × 109/L indicate a poor prognosis for patients with WM.
Acknowledgments
The authors thank the patients and their families.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Authors contributors
Cao XX, Yi SH, Jiang ZY, Li J and Qiu LG contributed to study conception and design; Cao XX, Yi SH, Jiang ZY, He JS, Yang W, Du J, Sun CY, Wu Y, Chen WM, Liu XJ, Li BZ, Li CR, Sang W, Liu QH, Chu XX, Li F, Bai O, Mao M, Fu R, Wang W, Liu LH, Wang LQ, Dong YJ, Luo J, Li ZL, Wei YQ, Zhang QK, Liu J, Ding KY, Zou L, Chen BY, Hua LM, Jing HM, He J, Wang L retrospectively reviewed patient records and contributed to data collection and patient follow-up; Cao XX, Yi SH and Jiang ZY contributed to data analysis; Cao XX wrote the paper; and all authors revised the paper and approved the submitted version.
Data availability statement
Individual participant data will not be available. Study protocol will be available beginning 9 months and ending 36 months following article publication at [email protected].